As-Needed Ruxolitinib Safe & Effective for Controlling AD Symptoms
An analysis of two phase 3 trials evaluated the effect of ruxolitinib cream in adult and...
Read MoreMar 23, 2023
An analysis of two phase 3 trials evaluated the effect of ruxolitinib cream in adult and...
Read MoreMar 23, 2023
In patients with psoriasis, retrospective data revealed that compared with phototherapy, a...
Read MoreMar 23, 2023
IL-31 inhibition with nemolizumab demonstrated improvement of various symptoms of prurigo...
Read MoreMar 23, 2023
For the treatment of hidradenitis suppurative (HS), the novel selective inhibitor of interleukin...
Read MoreMar 23, 2023
Dupilumab revealed superior efficacy compared with placebo in the phase 3 LIBERTY-AD-HAFT trial...
Read MoreMar 23, 2023
All our ASCO GI 2023 features in one convenient place! ASCO GI Cancer 2023.indd
Read MoreMar 23, 2023
For people who are HIV-positive (PWH), initiating ART with integrase strand transfer inhibitor...
Read MoreMar 22, 2023
Five low-risk, sleep-related factors have been associated with a lower risk of premature mortality...
Read MoreMar 22, 2023
A coordinated, multifaceted intervention proved effective in increasing the prescription of three...
Read MoreMar 22, 2023
The FREEDOM COVID Anticoagulation trial failed to demonstrate that therapeutic anticoagulation...
Read MoreMar 22, 2023
Sotatercept is a fusion protein that traps activins and growth differentiation factors involved in...
Read MoreMar 22, 2023
A collaborative analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials (N=31,245) showed that...
Read MoreMar 22, 2023
People with gender dysphoria on hormone replacement therapy (HRT) as part of gender affirmation...
Read MoreMar 22, 2023
The RENOVATE-COMPLEX-PCI trial showed that percutaneous coronary intervention (PCI) guided by...
Read MoreMar 22, 2023
In the placebo-controlled HALO trial, baxdrostat did not achieve a statistically significant...
Read MoreMar 22, 2023
The 3-year results of the Evolut Low Risk trial demonstrated durable benefits of transcatheter...
Read MoreMar 22, 2023
More intensive lipid lowering with the addition of evolocumab for 26 weeks was associated with a...
Read MoreMar 22, 2023
Physicians should be aware of the excess risk for severe hypoglycemia with concomitant use of...
Read More